Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38881
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bar, Jair | - |
dc.contributor.author | Peled, Nir | - |
dc.contributor.author | Schokrpur, Shiruyeh | - |
dc.contributor.author | Dudnik, Elizabeth | - |
dc.contributor.author | Wollner, Mira | - |
dc.contributor.author | Girard, Nicolas | - |
dc.contributor.author | Nana, Frank Aboubakar | - |
dc.contributor.author | Derijcke, Sofie | - |
dc.contributor.author | Kian, Waleed | - |
dc.contributor.author | Patel, Sandip P. | - |
dc.contributor.author | Sorotsky, Hadas Yocheved Gantz | - |
dc.contributor.author | Zer, Alona | - |
dc.contributor.author | Moskovitz, Mor | - |
dc.contributor.author | Metro, Giulio | - |
dc.contributor.author | Rottenberg, Yakir | - |
dc.contributor.author | Calles, Antonio | - |
dc.contributor.author | Hochmair, Maximilian | - |
dc.contributor.author | CUPPENS, Kristof | - |
dc.contributor.author | Decoster, Lynn | - |
dc.contributor.author | Addeo, Alfredo | - |
dc.date.accessioned | 2022-11-16T10:53:54Z | - |
dc.date.available | 2022-11-16T10:53:54Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-11-03T17:34:35Z | - |
dc.identifier.citation | JOURNAL OF CLINICAL ONCOLOGY, 40 (16) | - |
dc.identifier.uri | http://hdl.handle.net/1942/38881 | - |
dc.description.abstract | Background: About 10% of EGFR mutations (EGFRm) are 'uncommon mutations' (ucEGFRm). osimer-tinib is a 3 rd generation EGFRi, active against common EGFRm. We aimed to collect real-world data about systemic and brain response and resistance mechanisms to osimertinib for ucEGFRm patients. Methods: This is a multi-center, retrospective study of ucEGFRm mNSCLC treated with osimertinib as first EGFRi. RECIST and RANO-BM response was evaluated by investigators. Progression free survival (PFS), overall survival (OS) and duration of response (DOR) were calculated from initiation of osimerti-nib. Mutations found at resistance were collected. Results: 62 patients (pts) were identified in 22 centers from 9 countries. Median age was 64 (35-91) years, 74% females, 84% Caucasian, never/former/ current smokers were 48%/39%/11% respectively, ECOG PS was 0-1/2/3-4 in 84%/10%/5%. Histolo-gy was adenocarcinoma in 97%. The largest subgroups were G719X, de novo T790M and L861Q (Ta-ble). Compound EGFR mutations were found in 27 pts (44%), TP53 mutations in 21 pts (34%). In 17 cases (27%), compound mutations included the common L858R/deletion19 and/or de novo T790M. Most frequent metastatic sites were lung/bone/brain in 45%/44%/39%. Most frequent toxicities were gastrointestinal (32 pts, 52%) and skin (24 pts, 39%); 8 pts had grade 3-4 AEs. No grade 5 AE occurred. 3 pts had AEs leading to discontinuation. RECIST response (RR) was available for 53 pts, CR-4 (8%), PR-27 (51%), SD-17 (32%), and PD-5 (9%). Median DOR (mDOR) was 17.4 months (95% CI 9.1-NA). mPFS was 9.5 months (95% CI 8.5-17.4). mOS was 24.5 months (95% CI 17.4-35.1). See Table for efficacy in the major subgroups. 24 pts (39%) had brain metastasis at presentation , for 12 pts a brain response by RANO-BM was available with 25%/25%/33%/17% CR/PR/SD/PD. For 14 pts, rebiopsy mutation analysis at progression on osimertinib was available: 3 pts with an additional EGFR mutation (C797S,D585Y, E709K), 3 pts with a new TP53 mutation, 1 with c-Met amplification and 1 pt with transformation to neuroendocrine carcinoma. Conclusions: Osimertinib demonstrated activity in ucEGFRm with 91% disease control rate and encouraging PFS and DOR. Brain response was seen in 50% of cases. Several resistance mechanisms were identified. This report comprises, to the best of our knowledge, the largest dataset of osimertinib as the first EGFRi for ucEGFRm presented so far. Research Sponsor: AstraZeneca. | - |
dc.description.sponsorship | AstraZeneca | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.rights | 2022 by American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. | - |
dc.title | Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 16 | - |
dc.identifier.volume | 40 | - |
local.bibliographicCitation.jcat | M | - |
local.publisher.place | TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.isi | 000863680302294 | - |
local.provider.type | wosris | - |
local.description.affiliation | Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel. | - |
local.description.affiliation | Shaare Zedek Med Ctr, Oncol Div, Jerusalem, Israel. | - |
local.description.affiliation | Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA. | - |
local.description.affiliation | Assuta Med Ctr, Lung Canc Serv, Tel Aviv, Israel. | - |
local.description.affiliation | Rambam Hlth Care Campus, Haifa, Israel. | - |
local.description.affiliation | Curie Inst, Paris, France. | - |
local.description.affiliation | Clin Univ St Luc, Brussels, Belgium. | - |
local.uhasselt.international | yes | - |
item.fullcitation | Bar, Jair; Peled, Nir; Schokrpur, Shiruyeh; Dudnik, Elizabeth; Wollner, Mira; Girard, Nicolas; Nana, Frank Aboubakar; Derijcke, Sofie; Kian, Waleed; Patel, Sandip P.; Sorotsky, Hadas Yocheved Gantz; Zer, Alona; Moskovitz, Mor; Metro, Giulio; Rottenberg, Yakir; Calles, Antonio; Hochmair, Maximilian; CUPPENS, Kristof; Decoster, Lynn & Addeo, Alfredo (2022) Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms. In: JOURNAL OF CLINICAL ONCOLOGY, 40 (16). | - |
item.accessRights | Restricted Access | - |
item.fulltext | With Fulltext | - |
item.contributor | Bar, Jair | - |
item.contributor | Peled, Nir | - |
item.contributor | Schokrpur, Shiruyeh | - |
item.contributor | Dudnik, Elizabeth | - |
item.contributor | Wollner, Mira | - |
item.contributor | Girard, Nicolas | - |
item.contributor | Nana, Frank Aboubakar | - |
item.contributor | Derijcke, Sofie | - |
item.contributor | Kian, Waleed | - |
item.contributor | Patel, Sandip P. | - |
item.contributor | Sorotsky, Hadas Yocheved Gantz | - |
item.contributor | Zer, Alona | - |
item.contributor | Moskovitz, Mor | - |
item.contributor | Metro, Giulio | - |
item.contributor | Rottenberg, Yakir | - |
item.contributor | Calles, Antonio | - |
item.contributor | Hochmair, Maximilian | - |
item.contributor | CUPPENS, Kristof | - |
item.contributor | Decoster, Lynn | - |
item.contributor | Addeo, Alfredo | - |
crisitem.journal.issn | 0732-183X | - |
crisitem.journal.eissn | 1527-7755 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study)_ Updated results, brain efficacy, and resistance mechanisms_.pdf Restricted Access | Published version | 59.91 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.